

Tender Reference no.-BMSIC/DRUGS/18-03

S.N.	Technical Eligibility Criteria as per NIT	Firm Name - M/S DAFFODILS PHARMACEUTICALS LIMITED. Corporate Address :- JAWAHAR NAGAR, ROHTA ROAD, MEERUT (U.P.) Manufacturer Address :- JAWAHAR NAGAR, ROHTA ROAD, MEERUT (U.P.)
1	Constitution of the Bidding Company/Firm such as Memorandum of Association and Article of Association with complete address. As per Clause 3(c).	a) Scanned copy of Certificate of Incorporation (No. 7205 of 1985 dated 28.05.1985) issued by Registrar of Company Kanpur submitted. (Pg. No. 23) b) Scanned copy of Fresh Certificate of Incorporation consequent on change of name from M/s Daffodils Pharmaceutical PVT. LTD. to M/s Daffodils Pharmaceuticals Ltd. issued by Registrar of Company Kanpur on dated 06/06/1995 submitted. (Pg no.24) c) Scanned copy of Memorandum of Association dated 28.05.1987 of DAFFODILS PHARMACEUTICAL LTD. submitted. (Pg. No. 15 to 22) d) Scanned copy of Articles of Association dated 28.05.1987 of DAFFODILS PHARMACEUTICAL LTD. submitted. (Pg No. 8 to 14) e) Scanned copy of Form 32 regarding appointment of Managing Directors is submitted. (Pg. no. 66 to 69) f) Scanned copy of bidder Information/ Bidder details is submitted as per Annexure V of NIT. (Pg no. 102) g) Scanned copy of list of Directors signed by Sanjeev kumar Giri, Authorised Signatory submitted. (Pg. no. 65)
2	Power of Attorney or Resolution of Board by which the authorised signatory has been authorised by bidder firm to sign the documents. As per Clause 3 (e) of the NIT.	a) Scanned copy of Power of Attorney in favour of Mr. Sanjeev Kumar Giri to sign all tender documents against rate contract of drugs in tender floated by office of BMSICL, Patna submitted. (Pg. no. 4) b) Scanned copy of Extract of the Minute's of the meeting of the Board of Directors of M/s Daffodils Pharmaceuticals Ltd. held on 23.04.2018 is submitted wherein it is resolved that Mr. Sanjeev Kumar Giri, Authorised Signatory is being hereby authorized to purchase the tender paper in the name of the company, submit the tender, sign the documents on behalf of the company. He is further authorized to assign person/ person (s) to sign tender documents on behalf of the company. (Pg. no- 5)
3	List of item Quoted in prescribed format as Annexure III as per Clause 3 (o)	Scanned copy of List of Items quoted is submitted as per annexure III of NIT. (Total No. of items quoted-05) (Pg no. 43)

Amr
14/6/18

Amr
12/06/18

Amr
12.06.18

Amr
12/06/18

Amr
14/06/18

Amr
14/06/18

Amr
(1-16)

Amr
12/06/2018

- Minimum three years old valid manufacturing licence of the product quoted with latest license renewal certificate. As per clause 3(f).
- Approved product list as per the license issued for quoted drugs for minimum three years. As per clause 3(f).
- Manufacturing license along with approved product list must be valid till the last date of the submission of tender. As per clause 3(f).
- In Case of those drugs which are notified first time in IP 2014 then Manufacturing and Marketing license should be in any official compendium (USP/BP/IP) along with current valid license in IP in continuation.
- Market standing certificate & Manufacturing certificate issued by the Licensing Authority as a Manufacturer for each drug quoted for the last 3 years (Certificate should be enclosed with list of items) except for the drugs falling under the category of 'New Drug' as defined by CDSCO (Central Drugs Standard Control Organization). If permission in Form 46 from DCGI has been obtained, then the 3 years Manufacturing & Market standing clause will be relaxed. The provisions of Rule 122 E of Drugs and Cosmetics Act rule 1945 shall apply.
- For all regulated products, the bidder should have at least two years of manufacturing and marketing experience of the particular items as a manufacturer for each regulated product quoted in the tender. However, this would not apply to regulated products which have been licensed by DCGI less than two years ago. A certificate from DCGI (I) shall be required for all new regulated products to this effect.
- FFS (Flow Fill & Seal Process) Technology will be accepted wherever applicable.

Bidders shall submit self attested copies of required manufacturing license and approved product list in support of above mentioned condition and they are required to specify the quoted product in their approved product list by highlighting it. As per Clause 3(f)

a) Scanned Copy of Manufacturing Licence in Form 25 issued on 15.05.1996 by Drugs Controller, Uttar Pradesh is submitted wherein it is stated that License No-10 of 1996 of M/s Daffodilis Pharmaceuticals Ltd. Meerut, shall be in force from 15.05.1996 to 31.12.1997 (pg no.41)

b) Scanned Copy of Manufacturing Licence in Form 28 issued on 15.05.1996 by Drugs Controller, Uttar Pradesh is submitted wherein it is stated that License No-08/SC/P of 1996 of M/s Daffodilis Pharmaceuticals Ltd. Meerut, will be in force from 15.05.1996 to 31.12.1997 (pg no.42)

- Approved product list as per the license issued for quoted drugs for minimum three years As per clause 3(f).

of M/s Daffodilis Pharmaceuticals Ltd. Meerut, for the manufacture of the following categories of drugs other than those specified in Schedule C, C(1) & X, has been renewed from 01.01.2012 to 31.12.2016 (pg no.35)

Note-(i) The two highlighted sentences in form 26 are contradictory

(ii) Stamp and Seal of Drug Control Department is not observed in Form 26.

d) Scanned copy of approved product list by letter no DRUG/4162/1714 dated 18.03.2013 is submitted. (pg. No. 31 to 34)

NIT S. No.	Name of the Drug	specification	page no
------------	------------------	---------------	---------

24 sterile water for injection IP

Note- In submitted approved product list the bidder has highlighted water for injection in place of Sterile water for injection. S.W.F.I. is mandatory for parenteral Administration (IV/IM).

44	Miconazole Nitrate Cream IP	2% w/w	33
47	Doxycycline Capsule IP	100 mg	34
48	Diclofenac Diethylammonium Gel	1% w/w	32
55	Water for Injection IP	10 ml	31

Note- Sterile Water For Injection is mandatory for parenteral Administration (IV/IM).

e) Scanned Copy of Certificate of Renewal in Form 26 (Certificate of renewal of licence to manufacture for sale of drugs other than those specified in Schedule X) issued on 27.02.2017 by Drug Licensing and Controlling Authority, Uttar Pradesh is submitted wherein it is stated that License No-10 of 1996 & 08/SC/P of 1996 of M/s Daffodilis Pharmaceuticals Ltd. Meerut, for the manufacture of the following categories of drugs other than those specified in Schedule C, C(1) & X, has been renewed from 01.01.2017 to 31.12.2021 (pg no.40)

Note-(i) The two highlighted sentences in form 26 are contradictory.

(ii) Stamp and Seal of Drug Control Department is not observed in Form 26

f) Scanned copy of approved product list by letter no DRUG/4162/2486 dated 27.02.2017 is submitted. (pg. No. 36 to 39)

NIT S. No.	Name of the Drug	specification	page no
------------	------------------	---------------	---------

24	sterile water for injection IP	2 ml
----	--------------------------------	------

Note- In submitted approved product list the bidder has highlighted water for injection in place of Sterile water for injection. S.W.F.I. is mandatory for

Parenteral Administration (IV/IM).		
44	Miconazole Nitrate Cream IP	2% w/w
47	Doxycycline Capsule IP	100 mg
48	Parental Product name is mentioned as Doxycycline in place of Doxycycline.	
55	Diclofenac Diethylammonium Gel	1% w/w
	Water for Injection IP	10 ml

Note- Product name is mentioned as Doxycycline in place of Doxycycline.

Note-Sterile Water For Injection is mandatory for parenteral Administration (IV/IM)

b) Scanned Copy of Manufacturing and Marketing Certificate (No.Drug/671 dated 19/03/2018) issued by Drug Licensing cum controlling Authority, Uttar Pradesh is submitted wherein it is stated that M/s Daffodils Pharmaceuticals Ltd. is manufacturing the following products since the last three years. It is further certified that the following products are also being marketed for the last three years. product at NIT sl. no. 48, 47, 24 and 55 are mentioned in above certificate.

(Pg. No. 27 to 30)

h) Scanned Copy of Manufacturing and Marketing Certificate (No. Drug/4162/154 dated 18/01/2018) issued by Drug Licensing cum controlling Authority, Uttarakhand Pradesh is submitted wherein it is stated that M/s Daffodilis Pharmaceuticals Ltd. is manufacturing the following products since the last three years. It is further certified that the following products are also being marketed for the last three years. product at NIT sl. no. 44 is mentioned in above certificate.

454

5	In case of importer, the bidder (importer) firm must have minimum three years old valid invoices, statement and import license showing that the quoted product are being imported and sold in India by the bidder (importer) firm minimum for last three years. Import license must be valid on the last date of submission of tender. As per Clause 3(g)	N/A
6	Self attested copies of Market standing certificate (in India) of minimum three years, issued by the concerned Licensing Authority from Drugs Control Department for the quoted product. As per Clause 3(h)	N/A
7	Self attested copy of Non Conviction Certificate (NCC), issued by the concerned Licensing Authority from Drug Control Administration of the state for last three years. It should be not more than one year old. As per Clause 3(i).	Scanned copy of Non Conviction Certificate (No. Drug/4162/164 dated 18.01.2018) issued by Drug Licensing cum Controlling Authority Uttar Pradesh is Submitted wherein it is stated that M/s Daffodilis Pharmaceutical Limited has not been convicted by court of Law at any instance during the last five (5) years under Drugs & Cosmetics Act 1940 and Rules 1945. This certificate is valid for 6 month from the date of issue. (Pg. no. 7)
8	Self attested copies of WHO-GMP/GMP as per revised Schedule- 'M'/COPP Certificate of the manufacturing unit issued by the Licensing Authority / Drugs Control Department. The GMP certificate must not be older than one year form the last date of submission of tender. As per clause 3(j).	Scanned Copy of Certificate of Good Manufacturing Practices (No. Drug/4162/615 dated 19.01.2017) issued by Drug Licensing cum controlling Authority, Uttar Pradesh is Submitted. wherein it is Stated that on the basis of the inspection carried out o 16.12.2016 we certify that the site indicated on this certificate complies with Good Manufacturing Practices for the dosage forms, categories and activities listed in Table I. This certificate remains valid up to 18.01.2019. (Pg. No. 49) Note-- GMP certificate is older than one year but valid upto 18.01.2019
9	Self attested copies of Maximum Production Capacity Certificate (section wise) issued by concerned Licensing Authority from Drugs Control Department highlighting the quoted product section. In case of Importer An affidavit (With Stamp) sworn before first class magistrate/Notary stating the batch production capacity of the firm and also that said production (Importing) capacity shall be adequate for requirement laid in NIT. Importers will have also to submit Invoices/Evidence of import in items of said product with quantity details. As per Clause 3(k).	Scanned Copy of Capacity and Quality Certificate (No. Drug/4162/11566 dated 11-12-15) issued by Drugs Licensing and Controlling Authority Uttar Pradesh is submitted wherein it is stated that Annual Capacity for tab-50 Lac/day, Cap-12lac/day, Dry power inj 50000 vial/day, Injection & ophthalmic- 50000 Vials per/day, Ointment-900 kg per/day (Pg. No.2 & 3) Note:- Ampoule is not manufactured in the plant as per Capacity and Quality Certificate.
10	An affidavit (with stamp) sworn before first class magistrate/Notary stating that the firm & its quoted product is not black listed currently (as on the last date of submission of the tender) by Central Government/ Central Government Agencies/any state government/any of the state government agencies/any Drug Procurement Agencies or by BMSICL as per Annexure II (clause 3(n) of NIT).	Scanned Copy of Notarised Affidavit for Non Blacklisting is submitted wherein it is stated that there is a CBI case pending against one of the Ex- Director of the company for which U.P. Govt. had issued a circular on 21.08.2015. In which the UP Govt. had inform the local authorities that no local purchases against ESIC/TNMSC rate contract should be made from us. Further on 04.11.2016 Director Stores had issued a letter in which he had clearly clarified that the company has not been blacklisted/ debarred by the govt. of UP with reference to this Circular dated 21.08.2015. (Pg.No. 63 to 64)
11	EMD details (DD number/BG number and date with issuing bank) as per Clause 3(b).	ANDHRA BANK D.D No:- "880643" Rs.1,00,000/- Pgeno:-50
12	Tender Fee Rs 10,000/- in form of DD as per Clause 3(a).	ANDHRA BANK D.D No:- "880639" Rs.10,000/- Pgeno:-01
13	Self attested copies of the Audited Annual Balance Sheet and Profit and Loss statement showing details of their annual average turnover not less than 25 crores for any three of the last four consecutive financial years. (Auditor/ C.A. Certificate of turnover will not be accepted). As per Clause 3(l)	F.Y.-2014-2015 Rs.54.71 (in crore) Pgeno:-58 F.Y.-2015-2016 Rs.50.01 (in crore) Pgeno:-55 F.Y.-2016-2017 Rs.50.03 (in crore) Pgeno:-52
14	Self attested copy of Income Tax Return for any three of last four consecutive Assessment years. As per Clause 3(m).	F.Y.-2014-2015 Pgeno:-46 F.Y.-2015-2016 Pgeno:-45 F.Y.-2016-2017 Pgeno:-44
15	Self attested copy of PAN Card of the Bidder Company. As per Clause 3(p)	PAN no:- "AAACD5022G" Pg no:-06

453

16	Self attested copy of Certificate of valid GST registration of the bidder company. As per Clause 3(q)	Submitted	Pg no:-100
17	Affidavit (with stamp) declaration regarding acceptance of tender conditions to be submitted by the bidding firm as per Annexure IV (Clause 5(k) of NIT).	Scanned Copy of Notarised Affidavit regarding Acceptance of tender conditions is submitted as per annexure IV of NIT (Pg. No. 61)	
The facts in clause No-1 to 10 and 17 of the provided sheet has been complied with due diligence and care, on the basis of document provided by BMSICL, inspite, some inadvertent discrepancies could have been crept in. Humble request to all concerned to bring to notice in due time if any discrepancies are observed for rectification.			

(Signature)
12/09/18

(Signature)
12/09/18

(Signature)
12-09-18

(Signature)
12/09/18

(Signature)
12/09/18

(Signature)
12/08/18

(Signature)
12/06/18 *(A-3)*
(11-16)